MCM
JAZZ icon

Manchester Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Manchester Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.51K Sell
27
-5
-16% -$1.09K ﹤0.01% 864
2026
Q1 		$6.05K Hold
32
– – ﹤0.01% 870
2025
Q4 		$5.44K Buy
32
+8
+33% +$1.23K ﹤0.01% 874
2025
Q3 		$3.16K Hold
24
– – ﹤0.01% 1015
2025
Q2 		$2.55K Sell
24
-100
-81% -$10.9K ﹤0.01% 979
2025
Q1 		$15.4K Buy
124
+100
+417% +$13K ﹤0.01% 764
2024
Q4 		$2.96K Hold
24
– – ﹤0.01% 956
2024
Q3 		$2.67K Sell
24
-15
-38% -$1.64K ﹤0.01% 966
2024
Q2 		$4.16K Buy
39
+33
+550% +$3.63K ﹤0.01% 869
2024
Q1 		$723 Buy
+6
New +$735 ﹤0.01% 908

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Manchester Capital Management's JAZZ Position: Q2 2026 in Review

Manchester Capital Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 16% in Q2 2026, selling an estimated $1.09K and leaving 27 shares worth $6.51K. The position accounts for ﹤0.01% of the portfolio, ranked #864.

Manchester Capital Management first reported a position in JAZZ in Q1 2024 and has held it in 10 quarters since. The position peaked at $15.4K in Q1 2025. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Manchester Capital Management held 27 shares of Jazz Pharmaceuticals worth $6.51K as of Q2 2026.
  • Manchester Capital Management sold 5 Jazz Pharmaceuticals shares in Q2 2026, an estimated $1.09K.
  • Jazz Pharmaceuticals made up ﹤0.01% of Manchester Capital Management's portfolio in Q2 2026, its #864 holding.
  • Manchester Capital Management first reported a position in Jazz Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Manchester Capital Management's Jazz Pharmaceuticals position peaked at $15.4K in Q1 2025.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.